IHL - INCANNEX - HOLDERS RESEARCH, page-639

(apologies for the length of this post in advance)

and an important distinction between IHL 42x and the others in the 'race' for TGA only S3 registration of a CBD based drug candidate for sleep disturbance is the clinical pharmacological reference bank available to IHL in the phase II/III for 42x in relation to the BA/BE study to be run in parallel is extensive for both Dronabinol and Acetazolamide ( as they both carry registration with the FDA in their own right)...
the others are Avecho, McCann, Little Green Pharma and Chanelle McCoy health ( Cann Group who was leading that 'race' we now know about their outcome ...unfortunate for them but not even close to what IHL is executing ....none of them are )

the other obvious distinction is IHL are shooting for FDA registration / TGA S3 in parallel ....the others are only shooting for the lower bar of TGA registration ......which of course may be extremely problematic ( just my view there)
none of them are able to access such extensive drug pharmacological profile for CBD held with the FDA ( as there is only Epidiolex ) as IHL will surely do with 42x .......its a massive moat in its own right

Dronabinol (Rx - all prescription only)
currently 13 of 19
(click images for larger view)

selecting one at random

FDA dossier
https://fda.report/DailyMed/b60052fd-c0fd-4ec1-9774-81b3a48dbac5


Acetazolamide (Rx - all prescription only)
currently 26 tablet format / 5 injectables
partial list only


selecting one at random

FDA dossier
https://fda.report/DailyMed/abeb13eb-66a5-4030-9bc2-5981acd196b9

no wonder niche investors in the sector are looking to get coin into the companies most likely to succeed in the space an attract big pharma to the product .....and capture a market where there is no current oral medication to effect a 'cure' .....IHL is way out in front in my view ......

I'm just sitting back King k with these in the bottom draw letting JL and the team do their thing .....always remembering the market has nothing to do with the value of the company and what will unfold in 2023 and beyond .....and this of course is only 42x

that moat is the sound of the big boys knocking on the door